Gene Therapy Product (LX101) for Rpe65 Biallelic Mutation-Associated Inherited Retinal Degenerations (IRDs) Approved for Clinical Trial in China

On April 24, 2022, Shanghai Langsheng Biotechnology Co., Ltd., a subsidiary of Legend Capital's co-founded company Innostellar Biotherapeutics, announced that the clinical trial application of its product LX101 injection for the treatment of patients with Rpe65 biallelic mutation-associated inherited retinal degenerations (IRD) has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China.

Login Or Register To Read Full Story